Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,250,719 papers from all fields of science
Search
Sign In
Create Free Account
RP 49356
Known as:
RP-49356
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
aprikalim
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
The potassium channel opener RP 49356 modifies the ATP-sensitivity of K+-ATP channels in cardiac myocytes
D. Thuringer
,
D. Escande
Pflügers Archiv
2004
Corpus ID: 40805321
Introduct ion RP 49356, N-methyl-2-(3-pyridyl)-tetrahydrothiopyran -2-carbothioamide-l-oxide, is a potent vasorelaxant agent with…
Expand
2004
2004
Comparison of the effects of RP 49356, cromakalim and nifedipine on guinea-pig tracheain vitro
T. Brown
,
J. Sweetland
,
D. Raeburn
Pflügers Archiv
2004
Corpus ID: 36877801
Introduction RP 49356 and cromakalim (BRL 34915) relax various smooth muscle types by opening potassium (K +) channels in the…
Expand
1996
1996
Potassium channel openers inhibit ATP-induced cytosolic free calcium increase in cultured rabbit aortic smooth muscle cells.
D. Shi
,
Z. Guo
Zhongguo yao li xue bao = Acta pharmacologica…
1996
Corpus ID: 9820833
AIM To study the effects of potassium channel openers (PCO) on cytosolic free calcium ([Ca2+]i) changes and their possible…
Expand
1996
1996
Inhibitory effect of potassium channel openers on proliferation of cultured rabbit aortic smooth muscle cells.
D. Shi
,
Z. Guo
Zhongguo yao li xue bao = Acta pharmacologica…
1996
Corpus ID: 40964633
AIM To study the effects of pinacidil (Pin), nicorandil (Nic), RP 49356 (RP), and lemakalim (Lem) on phenylephrine (PE)-induced…
Expand
Highly Cited
1993
Highly Cited
1993
4-morpholinecarboximidine-N-1-adamantyl-N'-cyclohexylhydrochloride (U-37883A): pharmacological characterization of a novel antagonist of vascular ATP-sensitive K+ channel openers.
K. Meisheri
,
S. J. Humphrey
,
S. Khan
,
L. A. Cipkus-Dubray
,
M. P. Smith
,
A. W. Jones
Journal of Pharmacology and Experimental…
1993
Corpus ID: 35005711
This study describes the in vitro and in vivo characteristics of a guanidine 4-morpholinecarboximidine-N-1-adamantyl-N…
Expand
1993
1993
Synergistic effects of glyburide and U-37883A, two structurally different vascular ATP-sensitive potassium channel antagonists.
C. E. Ohrnberger
,
S. Khan
,
K. Meisheri
Journal of Pharmacology and Experimental…
1993
Corpus ID: 36648006
Glyburide, a sulfonylurea, and U-37883A, a guanidine (4-Morpholinecarboximidine-N-1-Adamantyl-N' cyclohexylhydrochloride), have…
Expand
1992
1992
Differential effects of endothelin‐1 on the vasorelaxant properties of benzopyran and non‐benzopyran potassium channel openers
K. Lawson
,
M. Barras
,
E. Zazzi‐Sudriez
,
Denis. Martin
,
J. Armstrong
,
P. Hicks
British Journal of Pharmacology
1992
Corpus ID: 32983333
1 . The effects of endothelin‐1 (ET‐1) on the vasorelaxant properties of structurally different potassium channel openers (PCOs…
Expand
Review
1990
Review
1990
The potassium channel openers: a new class of vasorelaxants.
A. Weston
,
J. Longmore
,
D. Newgreen
,
G. Edwards
,
K. Bray
,
S. Duty
Blood & Vessel
1990
Corpus ID: 46527677
Cromakalim, pinacidil, nicorandil, diazoxide and RP-49356 belong to the class of drugs termed potassium channel openers. In rat…
Expand
1990
1990
Effects of potassium channel openers on single potassium channels in mouse skeletal muscle
R. Weik
,
B. Neumcke
Naunyn-Schmiedeberg's Archives of Pharmacology
1990
Corpus ID: 8109036
SummaryThe patch-clamp technique was used to study the effects of the potassium channel openers cromakalim, pinacidil, RP 49356…
Expand
Highly Cited
1989
Highly Cited
1989
K+ channels openers prevent epilepsy induced by the bee venom peptide MCD.
G. Gandolfo
,
Claude Gottesmann
,
J. Bidard
,
Michel Lazdunski
European Journal of Pharmacology
1989
Corpus ID: 4555238
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE